Research programme: estrogen receptor alpha modulator therapeutics and diagnostics - Shenogen Pharma

Drug Profile

Research programme: estrogen receptor alpha modulator therapeutics and diagnostics - Shenogen Pharma

Alternative Names: SNG 1153; SNG 8003; SNG 8023; SNG-8006; SNG-8033; SNG-8038

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shenogen Pharma
  • Class Diagnostic agents; Drug conjugates; Monoclonal antibodies; Small molecules
  • Mechanism of Action Estrogen receptor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Chronic myeloid leukaemia; Endometrial cancer; Lung cancer; Unspecified
  • Discontinued Osteoporosis

Most Recent Events

  • 25 Jun 2018 China Food and Drug Administration grants approval to Shenogen Pharmaceutical for clinical trial of SGN 1153 in Cancer
  • 25 Jun 2018 Pharmacodynamics data from preclinical trials in Cancer released by Shenogen Pharmaceutical
  • 18 Oct 2016 Discontinued for Osteoporosis in China (unspecified route) (Shenogen Pharma pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top